Form 8-K - Current report:
SEC Accession No. 0001477932-25-003852
Filing Date
2025-05-15
Accepted
2025-05-15 17:26:48
Documents
16
Period of Report
2025-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vnrx_8k.htm   iXBRL 8-K 28134
2 PRESS RELEASE vnrx_ex991.htm EX-99.1 20163
  Complete submission text file 0001477932-25-003852.txt   178722

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnrx-20250515.xsd EX-101.SCH 5874
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnrx-20250515_lab.xml EX-101.LAB 14667
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnrx-20250515_cal.xml EX-101.CAL 898
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnrx-20250515_pre.xml EX-101.PRE 9275
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnrx-20250515_def.xml EX-101.DEF 2099
18 EXTRACTED XBRL INSTANCE DOCUMENT vnrx_8k_htm.xml XML 3904
Mailing Address 1489 WEST WARM SPRINGS ROAD SUITE 110 HENDERSON NV 89014
Business Address 1489 WEST WARM SPRINGS ROAD SUITE 110 HENDERSON NV 89014 1 (646) 650-1351
VOLITIONRX LTD (Filer) CIK: 0000093314 (see all company filings)

EIN.: 911949078 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36833 | Film No.: 25955983
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)